Clinical treatment of anemia in chronic kidney disease with oral hypoxia-inducible factor prolyl hydroxylase inhibitors that stimulate endogenous EPO production to increase hemoglobin may be as effective as erythropoiesis-stimulating agents67,68, and the metabolic responses to this new class of drugs remain to be determined. The gene discussed is EPO; the disease is anemia (phenotype).